Skip to main content
Clinical Trials/CTRI/2021/04/032795
CTRI/2021/04/032795
Not yet recruiting
Phase 4

Role of High Flow Nasal Cannula (HFNC) as a treatment modality in patients with hypoxemic respiratory failure due to COVID - 19

Government Medical College Vadodara0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Government Medical College Vadodara
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Government Medical College Vadodara

Eligibility Criteria

Inclusion Criteria

  • COVID â?? 19 pneumonia (Diagnosed with polymerase chain reaction)
  • Age more than 18 years of either gender
  • Acute Hypoxemic Respiratory Failure
  • Admission to intensive care unit
  • Supported by high flow nasal cannulae

Exclusion Criteria

  • Intubation prior to HFNC therapy
  • Uncooperative and neurologically (Glasgow coma scale less than equal to 12\) unstable patients
  • Patients with haemodynamic instability
  • Patients with primary pulmonary disease, respiratory acidosis in the first blood gases (pH \< 7\.2,pCO2 \>\= 50\)
  • In all conditions where PEEP is contraindicated like in presence of pneumothorax, large bullae in lungs or haemodynamic instability.
  • Patient not accepting nasal cannula due to irritation or discomfort

Outcomes

Primary Outcomes

Not specified

Similar Trials